Follow The Filings

APRE Aprea Therapeutics Inc.

Health Care, filed as APREA THERAPEUTICS INC (COM NEW), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by APRE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All APRE insider trades
  • $61K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Oren Gilad CEO
    Buy
    $25K 28,100 shares at $0.8900 +8.1% to stake
    Traded Jan 30 Filed Feb 2
    ↗
  2. John P. Hamill CFO
    Buy
    $5,073 5,700 shares at $0.8900 +21% to stake
    Traded Jan 30 Filed Feb 2
    ↗
  3. Marc Duey Director
    Buy
    $25K 21,459 shares at $1.17 +9.1% to stake
    Traded Dec 10, 2025 Filed Dec 11, 2025
    ↗
  4. John P. Hamill CFO
    Buy
    $5,825 5,000 shares at $1.17 +22% to stake
    Traded Dec 10, 2025 Filed Dec 11, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 10 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 3.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
424B7 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
424B3 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
424B3 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$14.29M -$12.96M -$12.6M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $22.52M $23.58M $15.56M
Total non-current assets * $129,079 $403,354 $372,155
Total assets $22.65M $23.98M $15.93M
Total current liabilities $4.39M $3.36M $2.76M
Total equity $16.95M $19.31M $12.44M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$12.18M -$13.56M -$12.89M
Cash from investing -$93,093 -$15,478 —
Cash from financing $5.14M $14.82M $4.64M
Net change in cash * -$7.13M $1.25M —

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.